Literature DB >> 25286910

Medication-overuse headache in China: clinical profile, and an evaluation of the ICHD-3 beta diagnostic criteria.

Zhao Dong1, Xiaoyan Chen1, Timothy J Steiner2, Lei Hou1, Hai Di1, Mianwang He1, Wei Dai1, Meiyan Pan1, Mingjie Zhang1, Ruozhuo Liu1, Shengyuan Yu3.   

Abstract

BACKGROUND: Although medication-overuse headache (MOH) is common in China, its clinical profile is not yet fully established. Meanwhile, ICHD-3 beta has been published, but its diagnostic criteria require further validation.
METHODS: We retrospectively classified the clinical features of 240 consecutive patients with MOH (55 males, 185 females), whose demographic data, headache features, overused medications (type, quantity, frequency and duration of use), headache-attributed burden, and outcomes were reviewed. We then applied the criteria of the several versions of ICHD (II, IIR and 3-beta) to these patients.
RESULTS: Compared with those with other headaches, patients with MOH were more likely to be less well educated (64.6% vs 42.0% for secondary school or lower, p < 0.0001), and on lower annual incomes (72.3% vs 56.0% for an income of Chinese yuan (CNY) 30,000 or less, p < 0.0001). Combination analgesics were the most commonly overused medications, and, caffeine (89.9%), aminopyrine (70.0%), phenacetin (53.9%) and phenobarbital (48.8%) were the most commonly used specific components of these. Only two patients (0.8%) had previously been given the diagnosis of MOH; accordingly, the median time to diagnosis after the estimated onset of the disorder was 4.0 years. The majority of patients (83.7%) improved with treatment. All 240 patients fulfilled the diagnostic criteria for MOH according to ICHD-3 beta; only 134 (55.8%) satisfied the diagnostic criteria for definite MOH according to ICHD-II, while 195 (81.2%) met those of ICHD-IIR.
CONCLUSIONS: MOH in China is associated with lower educational level and annual income. MOH has rarely been diagnosed and correctly treated in China. ICHD-3 beta appears to be more appropriate for the diagnosis of MOH than previous versions. © International Headache Society 2014.

Entities:  

Keywords:  China; ICHD-3 beta; Medication-overuse headache; clinical features; diagnostic criteria

Mesh:

Year:  2014        PMID: 25286910     DOI: 10.1177/0333102414552533

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  11 in total

1.  Field testing of the ICHD-3β and expert opinion criteria for chronic migraine.

Authors:  Huahua Jiang; Yong Deng; Yixin Zhang; Jieli Jin; Xueying Kong; Qiuwen Zhu; Kuiyun Wang; Jiying Zhou
Journal:  J Headache Pain       Date:  2016-09-19       Impact factor: 7.277

2.  Mindfulness Meditation for Primary Headache Pain: A Meta-Analysis.

Authors:  Qiang Gu; Jin-Chao Hou; Xiang-Ming Fang
Journal:  Chin Med J (Engl)       Date:  2018-04-05       Impact factor: 2.628

3.  Morphometric changes over the whole brain in caffeine-containing combination-analgesic-overuse headache.

Authors:  Xiaoyan Chen; Zhiye Chen; Zhao Dong; Mengqi Liu; Shengyuan Yu
Journal:  Mol Pain       Date:  2018 Jan-Dec       Impact factor: 3.395

Review 4.  Caffeine and Primary (Migraine) Headaches-Friend or Foe?

Authors:  Karl B Alstadhaug; Anna P Andreou
Journal:  Front Neurol       Date:  2019-12-03       Impact factor: 4.003

5.  Prevalence and risk factors associated with headache amongst medical staff in South China.

Authors:  Wei Xie; Ruibing Li; Mianwang He; Fang Cui; Tingting Sun; Jianmei Xiong; Dengfa Zhao; Weinan Na; Ruozhuo Liu; Shengyuan Yu
Journal:  J Headache Pain       Date:  2020-01-14       Impact factor: 7.277

6.  The impact of COVID-19 pandemic on headache symptoms and drug withdrawal among patients with medication overuse headache: a cross-sectional study.

Authors:  Changling Li; Yanbo Li; Mengmeng Ma; Yang Zhang; Jiajia Bao; Wenjing Ge; Yanqin Liu; Cheng Peng; Li He
Journal:  J Headache Pain       Date:  2021-05-21       Impact factor: 7.277

7.  Analysis of risk factors for medication-overuse headache relapse: a clinic-based study in China.

Authors:  Zhihui Yan; Yuan Chen; Chunfu Chen; Congcong Li; Xiaojun Diao
Journal:  BMC Neurol       Date:  2015-09-17       Impact factor: 2.474

8.  Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study.

Authors:  Ninett Louise Find; Rossana Terlizzi; Signe Bruun Munksgaard; Lars Bendtsen; Cristina Tassorelli; Giuseppe Nappi; Zaza Katsarava; Miguel Lainez; Maria Teresa Goicochea; Beatriz Shand; Ricardo Fadic; Santiago Spadafora; Marco Pagani; Rigmor Jensen
Journal:  J Headache Pain       Date:  2016-03-08       Impact factor: 7.277

9.  Comprehensive Application of the International Classification of Headache Disorders Third Edition, Beta Version.

Authors:  Byung-Kun Kim; Soo-Jin Cho; Byung-Su Kim; Jong-Hee Sohn; Soo-Kyoung Kim; Myoung-Jin Cha; Tae-Jin Song; Jae-Moon Kim; Jeong Wook Park; Min Kyung Chu; Kwang-Yeol Park; Heui-Soo Moon
Journal:  J Korean Med Sci       Date:  2015-12-24       Impact factor: 2.153

Review 10.  The Ambiguous Role of Caffeine in Migraine Headache: From Trigger to Treatment.

Authors:  Magdalena Nowaczewska; Michał Wiciński; Wojciech Kaźmierczak
Journal:  Nutrients       Date:  2020-07-28       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.